Journal Article

Challenges and improvements in HER2 scoring and histologic evaluation: insights from a national proficiency testing scheme for breast cancer diagnosis in China

Zhou, Quan, Li, Lin, Ma, Fei, Rao, Wei, Wang, Xin, Guo, Changyuan, Guo, Lei, Yang, Wenjing, Xu, Liwei, Wang, Bingning, Mu, Jiali, Yang, Lin, Xue, Xuemin, Xue, Weicheng, Ying, Jianming, Yuan, Pei, Li, Jiangtao

2024

Overview

Background In 2022, our team launched the pioneering national proficiency testing (PT) scheme for the pathological diagnosis of breast cancer, rapidly establishing its credibility throughout China. Aiming to continuously monitor and improve the proficiency of Chinese pathologists in breast pathology, the second round of the PT scheme was initiated in 2023, which will expand the number of participating institutions, and will conduct a nationwide investigation into the interpretation of HER2 0, 1+, and 2+/FISH- categories in China. Methods The methodology employed in the current round of PT scheme closely mirrors that of the preceding cycle in 2022, which is designed and implemented according to the “Conformity assessment—General requirements for proficiency testing”(GB/T27043—2012/ISO/IEC 17043:2010). More importantly, we utilized a statistics-based method to generate assigned values to enhance their robustness and credibility. Results The final PT results, published on the website of the National Quality Control Center for Cancer ( http://117.133.40.88:3927 ), showed that all participants passed the testing. However, a few institutions demonstrated systemic biases in scoring HER2 0, 1+, and 2+/FISH- with accuracy levels below 59%, considered unsatisfactory. Especially, the concordance rate for HER2 0 cases was only 78.1%, indicating challenges in distinguishing HER2 0 from low HER2 expression. Meanwhile, areas for histologic type and grade interpretation improvement were also noted. Conclusions Our PT scheme demonstrated high proficiency in diagnosing breast cancer in China. But it also identified systemic biases in scoring HER2 0, 1+, and 2+/FISH- at some institutions. More importantly, our study highlighted challenges in the evaluation at the extreme lower end of the HER2 staining spectrum, a crucial area for further research. Meanwhile, it also revealed the need for improvements in interpreting histologic types and grades. These findings strengthened the importance of robust quality assurance mechanisms, like the nationwide PT scheme conducted in this study, to maintain high diagnostic standards and identify areas requiring further training and enhancement.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Accreditation / Agreements / Biomarkers, Tumor / Biomedical and Life Sciences / Biomedicine / Breast cancer / Breast Neoplasms - diagnosis / Breast Neoplasms - metabolism / Breast Neoplasms - pathology / Breast pathology / Cancer / Cancer Research / China / Cloning / Conformity / Diagnosis / ErbB-2 protein / Female / HER2 / Hospitals / Humans / Immunohistochemistry / In Situ Hybridization, Fluorescence - standards / Laboratory Proficiency Testing / Medical tests / Oncology / Pathologists / Pathology / Proficiency testing / Quality assurance / Quality control / Receptor, ErbB-2 - metabolism / Surgical Oncology